{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:57:10Z","timestamp":1782953830856,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10147-018-1319-y","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T03:50:02Z","timestamp":1532058602000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Bevacizumab combined with platinum\u2013taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-5700","authenticated-orcid":false,"given":"Shinichi","family":"Komiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokuni","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Asai-Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kamiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"key":"1319_CR1","unstructured":"Cancer Registry and Statistics (2018) Cancer Information Service, National Cancer Center, Japan. \n                    https:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/index.html\n                    \n                  . Accessed Mar 2018"},{"key":"1319_CR2","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L et al (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061. \n                    https:\/\/doi.org\/10.1038\/nrdp.2016.61","journal-title":"Nat Rev Dis Primers"},{"key":"1319_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"1319_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, at al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"1319_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","volume":"76","author":"S Niho","year":"2012","unstructured":"Niho S, Kunitoh H, Nokihara H et al (2012) Randomized phase II study of first-line carboplatin\u2013paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362\u2013367","journal-title":"Lung Cancer"},{"key":"1319_CR6","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549\u20132556","journal-title":"J Clin Oncol"},{"key":"1319_CR7","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A Bois du","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW et al (2014) Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32:3374\u20133382","journal-title":"J Clin Oncol"},{"key":"1319_CR8","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1097\/MD.0000000000000975","volume":"94","author":"Z Chen","year":"2015","unstructured":"Chen Z, Zhong B, Lun X et al (2015) Specific safety profile of bevacizumab in Asian patients with advanced NSCLC: a meta-analysis. Medicine (Baltimore) 94:e975","journal-title":"Medicine (Baltimore)"},{"key":"1319_CR9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. \n                    https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40\n                    \n                  . Accessed Mar 2018"},{"key":"1319_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1319_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","volume":"27","author":"AM Oza","year":"2017","unstructured":"Oza AM, Selle F, Davidenko I et al (2017) Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA Single-Arm Phase 3B Study. Int J Gynecol Cancer 27:50\u201358","journal-title":"Int J Gynecol Cancer"},{"key":"1319_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","volume":"32","author":"RA Burger","year":"2014","unstructured":"Burger RA, Brady MF, Bookman MA et al (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 32:1210\u20131217","journal-title":"J Clin Oncol"},{"key":"1319_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT et al (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738\u2013748","journal-title":"N Engl J Med"},{"key":"1319_CR14","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584\u20132589","journal-title":"Cancer"},{"key":"1319_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM et al (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370\u2013376","journal-title":"Gynecol Oncol"},{"key":"1319_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1756-9966-31-53","volume":"31","author":"M Takano","year":"2012","unstructured":"Takano M, Tsuda H, Sugiyama T (2012) Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res 31:53. \n                    https:\/\/doi.org\/10.1186\/1756-9966-31-53","journal-title":"J Exp Clin Cancer Res"},{"key":"1319_CR17","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","volume":"34","author":"T Sugiyama","year":"2016","unstructured":"Sugiyama T, Okamoto A, Enomoto T et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG Trial. J Clin Oncol 34:2881\u20132887","journal-title":"J Clin Oncol"},{"key":"1319_CR18","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1158\/1535-7163.MCT-10-0169","volume":"9","author":"S Mabuchi","year":"2010","unstructured":"Mabuchi S, Kawase C, Altomare DA et al (2010) Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 9:2411\u20132422","journal-title":"Mol Cancer Ther"},{"key":"1319_CR19","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/jog.13450","volume":"43","author":"T Saito","year":"2017","unstructured":"Saito T, Takahashi F, Katabuchi H (2017) Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009. J Obstet Gynaecol Res 43:1667\u20131677","journal-title":"J Obstet Gynaecol Res"},{"issue":"Suppl 10","key":"1319_CR20","doi-asserted-by":"publisher","first-page":"x111","DOI":"10.1093\/annonc\/mds300","volume":"23","author":"J Prat","year":"2012","unstructured":"Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol 23(Suppl 10):x111\u20137","journal-title":"Ann Oncol"},{"key":"1319_CR21","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23:2605\u20132612","journal-title":"Ann Oncol"},{"key":"1319_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2017.04.011","volume":"146","author":"MA Bookman","year":"2017","unstructured":"Bookman MA, Tyczynski JE, Espirito JL et al (2017) Impact of primary platinum-free interval and BRCA1\/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol 146:58\u201363","journal-title":"Gynecol Oncol"},{"key":"1319_CR23","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1002\/cncr.29481","volume":"121","author":"S Lheureux","year":"2015","unstructured":"Lheureux S, Karakasis K, Kohn EC et al (2015) Ovarian cancer treatment: the end of empiricism? Cancer 121:3203\u20133203","journal-title":"Cancer"},{"issue":"suppl","key":"1319_CR24","doi-asserted-by":"publisher","first-page":"abstr 5506","DOI":"10.1200\/JCO.2018.36.15_suppl.5506","volume":"36","author":"S Pignata","year":"2018","unstructured":"Pignata S, Lorusso D, Joly F et al (2018) Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial: MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 36(suppl):abstr 5506","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1319-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T12:14:09Z","timestamp":1567080849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1319-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1319-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,20]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SK and TM have received speaker\u2019s honoraria from Chugai Pharmaceutical. TT, NT, and TS have received speaker\u2019s honoraria from Chugai Pharmaceutical and AstraZeneca. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}